The fast majority of patients (estimate of 90%) are diagnosed and managed in primary care settings. With an estimate of 1/3 of all patients an average primary care professional consults on a daily basis

GPcardio aims to connect health care professionals and societies active in Primary care worldwide in our mission to address the growing burden of cardiovascular, cardiometabolic and cardiorenal disease

In a population-based study, researchers found that both the relative genetic risk, assessed through a polygenic risk score and the absolute clinical risk, evaluated by SCORE2, independently contribute to an individual's overall CVD risk.

GPcardio is planning to update the EPCCS Practice Guidance documents to the broader spectrum of cardiovascular and related diseases by translating specialist guidelines to relevance for primary care

Prof Jakovljevic provides a brief overview of the STRATIFYHF study, an AI-based decision support system that could change the ways which heart failure is diagnosed and being managed

Prof. Seferovic highlights the importance of the STRATIFYHF study aiming to support early diagnosis of heart failure in Primary and Secondary care, by using an AI-based decision support system

At ACC.24, Dr. Alexander Blood shared insights from the DRIVE study, which examined the effectiveness of a remote program integrating patient education and medication management in increasing prescriptions for SGLT2 inhibitors and GLP-1RAs among type 2 diabetes (T2D) patients at elevated cardiovascular (CV) and/or renal risk

In a recent study presented at ACC.24, it was found that over 90% of patients correctly identified their suitability for nonprescription access to low-dose rosuvastatin using an innovative web application. This treatment proved to be safe overall and resulted in a significant 36% reduction in LDL cholesterol levels.

At ACC.24, Dr. Alexander Fanaroff presented findings from the BE ACTIVE trial, demonstrating how gamification and financial incentives effectively boosted physical activity among patients at risk for cardiovascular events over a 12-month intervention period.

STRATIFY-HF will develop, validate and implement the first AI-based, decision support system (DSS) for risk stratification, early diagnosis, and disease progression assessment in HF to accommodate both primary and secondary care clinical needs.

Primary care practitioners should note a significant global shift from underweight to obesity dominance over the past three decades, as revealed by an analysis of 3663 population-based studies.

In a substudy of SURMOUNT-1, tirzepatide reduced ambulatory blood pressure in adults with a BMI ≥27 kg/m² compared with placebo.